Predict your next investment

Alethia BioTherapeutics company logo
HEALTHCARE | Biotechnology
alethiabio.com

See what CB Insights has to offer

Founded Year

2002

Stage

Unattributed | Alive

Total Raised

$17.8M

Last Raised

$1.6M | 3 yrs ago

About Alethia BioTherapeutics

Alethia BioTherapeutics is a biotechnology company that develops monoclonal antibody therapeutics to clinically relevant targets identified using its STAR discovery technology.

Alethia BioTherapeutics Headquarter Location

141, President-Kennedy Ave. Suite SB-5100

Montreal, Quebec, H2X 1Y4,

Canada

514-858-7666

Latest Alethia BioTherapeutics News

Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5

May 21, 2020

| Source: Alethia Biotherapeutics multilang-release MONTREAL, May 21, 2020 (GLOBE NEWSWIRE) -- Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its Phase 2 Investigational new drug (IND) application for AB-16B5, a potent inhibitor of the epithelial to mesenchymal transition (EMT). This allows the Company to initiate a multi-center trial of AB-16B5 in combination with docetaxel in previously treated subjects with metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody. “We are extremely pleased to have achieved this important milestone in the development of AB-16B5 and to continue to advance the clinical development of this promising antibody” commented Yves Cornellier, President and CEO of Alethia. “EMT is a central enabler for solid tumor progression because it triggers metastatic invasion, resistance to several classes of anti-cancer drugs and contributes to immune evasion. There is also increasing evidence that EMT contributes to resistance to immune checkpoint inhibitors. AB-16B5 may play an important role in overcoming these problems”, added Dr. Mario Filion, Chief Scientific Officer. Study overview This multicenter, open-label, Phase 2 study of AB-16B5 in combination with docetaxel (NCT04364620) will enroll approximately 40 subjects with advanced NSCLC who have previously been treated with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, a patient population with very limited options. The primary objectives are to assess the anti-tumor efficacy of AB-16B5 in combination with docetaxel as measured by objective response rate and to determine the safety and tolerability of the combined drugs. Secondary objectives of the study include clinical benefit rate, percentage of subjects with complete response or partial response, duration of stable disease, progression-free survival and overall survival. About AB-16B5 AB-16B5 is a humanized IgG2 monoclonal antibody that selectively binds and inhibits tumor-associated secreted clusterin, a protein expressed in many cancers. Tumor-associated secreted clusterin is induced early in the EMT cascade and its inhibition with AB-16B5 stops and reverts EMT in animal models. A Phase 1 study in subjects with advanced carcinomas demonstrated that AB-16B5 was safe and well tolerated and provided clinical benefit to several subjects. Stable disease was observed in several patients for up to one year. There was also evidence of EMT inhibition in tumor biopsies. About Alethia Biotherapeutics Alethia is a privately held clinical stage biotechnology company located in Montreal. Alethia develops immunotherapeutics for the treatment of cancer. Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alethia BioTherapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alethia BioTherapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Alethia BioTherapeutics Patents

Alethia BioTherapeutics has filed 25 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Transcription factors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/25/2016

11/28/2017

Immunology, Clusters of differentiation, Units of information, Immune system, Monoclonal antibodies for tumors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

4/25/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/28/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Clusters of differentiation, Units of information, Immune system, Monoclonal antibodies for tumors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Alethia BioTherapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alethia BioTherapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.